Ludwig Institute for Cancer Research Limited

Other

Molmed Spa

Glycostem Therapeutics B.v.

Ludwig Institute

Catia Traversari

Etienne De Plaen

Pierre Van Der Bruggen

Thierry R Boon-Falleur

Aline Van Pel

Christophe Lurquin

Benoit Van Den Eynde

Vincent Brichard

Thierry Boon

Thomas Wolfel

Beatrice Gaugler

Patrick Chomez

Katharina Fleischauer

Pierre G Coulie

Christophe Lurguin

Pascal Chaux

Vincent Stroobant

Pedro Romero

Nathalie Demotte

Guy R Cornelis

Claudio Bordignon

Rosalie Luiten

Marie-Therese Duffour

Thomas W&ouml;lfel

Guy Warnier

Christoph Lurquin

Thiery Boon-Falleur

Thomas W Olfel

Jan Spanholtz

Nina Kok

Alessandra Gatti

Giuliana Vallanti

Marie-Thérèse Duffour

Erwin Schultz

A method of manufacturing of Natural Killer (NK) Cells genetically modified with lentiviral vectors carrying a polynucleotide coding for a Chimeric Antigen Receptors (CARs). CAR-NK cells obtained with the method, and the use of the CAR-NK cells in medicine, in particular for use in a method of treating cancer is also disclosed.

CAR NK cells

The invention relates to an isolated DNA sequence which codes for an antigen expressed by tumor cells which is recognized by cytotoxic T cells, leading to lysis of the tumor which expresses it. Also described are cells transfected by the DNA sequence, and various therapeutic and diagnostic uses arising out of the properties of the DNA and the antigen for which it codes.

Isolated tumor rejection antigen precursor proteins MAGE-2 and MAGE-3

A delivery system comprising a T cell comprising at least one antigen capable of loading antigen-presenting-cells with the antigen.

Antigen transduced T cells used as a delivery system for antigens

Nucleic acid molecules encoding the MAGE-1 tumor rejection antigen precursor

The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for MAGE-1 and MAGE-4, respectively. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinant Yersinia, recombinant Salmonella, or recombinant viruses. The present invention further relates to the MAGE-1 and MAGE-4 antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.

Tumor antigens and CTL clones isolated by a novel procedure

The invention involves the reception of particular nonapeptides by HLA molecules. The nonapeptides are derived from expression products of the MAGE gene family. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Method for treating cancer by administering MAGE-derived peptides

The invention involves a nonapeptide derived from the tumor rejection antigen precursor encoded by gene MAGE-3. This nonapeptide is presented by the HLA molecule HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Method for screening for cancer using binders for MAGE related peptides and complexes of the peptide and HLA molecules

Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These &ldquo;T-RAS&rdquo; bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.

Method for stimulating CTLs with peptides

The invention involves nonapeptides bound by HLA molecules such as HLA-A1. The resulting complexes are identified by cytolytic T cells. Such recognition may be used in diagnostics, or therapeutically.

Isolated nonapeptides presented by HLA molecules, and uses thereof

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or 'TRAP&rdquo;, is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Methods for treating subjects with disorders characterized by expression of tumor rejection antigen precursors

Isolated nonapeptides which bind to HLA molecules and provoke lysis by

Tumor rejection antigens derived from tumor rejection precursor MAGE-3 have been identified. These 'TRAS' bind to the MHC-class I molecule HLA-A2, and the resulting complexes stimulate the production of cytolytic T cell clones which lyse the presenting cells. The peptides and complexes may be used diagnostically, therapeutically, and as immunogens for the production of antibodies, or as targets for the generation of cytolytic T cell clones.

Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or `TRAP', is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Precursor processed to at least one tumor rejection antigen presented by

Tumor rejection antigen precursors, tumor rejection antigens and uses

The invention relates to nucleic acid molecules coding for a tumor rejection antigen precursor. Specifically, the tumor rejection antigen precursor, or 'TRAP', is processed into at least one tumor rejection antigen, which is presented by HLA-A2 molecules. Ramifications of the discovery are also set forth.

Isolated nucleic acid sequence coding for a tumor rejection antigen

Growing community of inventors

Milan, Italy

Catia Traversari